Signal from the log
CellsBin
montant non divulgué · Series A · United States · Diagnostics
CellsBin détecte et caractérise les cellules rares dans un échantillon, en combinant microfluidique, imagerie multimodale, analyse cellule par cellule et apprentissage automatique. Les premiers usages visés sont le suivi des thérapies cellulaires et géniques et les cancers du sang. Le communiqué nomme le chef de file, 108 BioCapital, mais ne donne aucun montant.
Spotted
Announced on , logged by the watch of 22 September 2026.
- Operation
- Funding round
- Announced amount
- montant non divulgué
- Stage
- Series A
- Country
- United States
- Sector
- Diagnostics
What the log says
Editorial note, in French
Repérée par la collecte. Personne ne l'a encore instruite.
The investors
Led by 108 BioCapital
Provenance
Source prnewswire
Logged on 22 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Spotted The collection saw this operation and logged it. Nobody has processed it yet, so what is shown is still an automatic reading of the source headline.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.